1286650

Fulvestrant

United States Pharmacopeia (USP) Reference Standard

• Synonym(e): (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluorpentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3,17-diol, Faslodex, ICI 182.780, ZD 182780, ZD 9238, ZM 182780
• Empirische Formel (Hill-System): C₃₂H₄₇F₅O₃S
• CAS-Nummer: 129453-61-8
• Molekulargewicht: 606.77
• MDL-Nummer: MFCD00903953
• UNSPSC-Code: 41116107
• PubChem Substanz-ID: 329749913
• NACRES: NA.24

Eigenschaften

• Qualität: pharmaceutical primary standard
• API-Familie: fulvestrant
• Hersteller/Markenname: USP
• Anwendung(en): pharmaceutical (small molecule)
• Format: neat
• Lagertemp.: 2-8°C
• SMILES String: [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24
• InChI: 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChIKey: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• Angaben zum Gen: human ... ESR1(2099) , ESR2(2100)

Beschreibung

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

• Targeted Radiation Drug for Breast Cancer: Fulvestrant was utilized in fluorocarbon nanoparticles combined with iodine-131, demonstrating potential as a targeted radiation drug for endocrine therapy in breast cancer treatment, enhancing the applicability of Fulvestrant in advanced therapeutic approaches (Zhi et al., 2024).


• Pharmacological Insights: A comprehensive review discussed novel oral selective estrogen receptor degraders, including Fulvestrant, detailing their mechanism and efficacy in breast cancer treatment, providing crucial insights for ongoing pharmaceutical research and development (Guglielmi et al., 2024).


• Quantification in Clinical Practice: Development of an LC-MS/MS method for the simultaneous quantification of four hormone therapy drugs, including Fulvestrant, in breast cancer patients supports its clinical application and monitoring, ensuring effective patient management and therapy optimization (Mansour et al., 2024).

Biochem./physiol. Wirkung

Fulvestrant (ICI 182.780) ist ein selektiver Östrogenrezeptor-Herunterregulator (SERD). Fulvestrant ist ein hochaffiner Östrogenrezeptor-Antagonist. IC₅₀ = 0,29 nM. Fulvestrant ist das erste „reine“ Antiöstrogen, das keine agonistische Wirkung hat, sowohl in vitro als auch in vivo.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Sicherheitshinweise

• H-Sätze: H413
• P-Sätze: P273 - P501
• Gefahreneinstufungen: Aquatic Chronic 4
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable